Zein nanoparticles for oral folic acid delivery 1 2 3 4 Authors Rebeca Peñalva <sup>a</sup>, Irene Esparza <sup>a</sup>, Carlos J. González-Navarro <sup>b</sup>, Gemma 5 Quincoces <sup>c</sup>, Ivan Peñuelas <sup>c</sup>, Juan M. Irache <sup>a</sup> 6 7 8 Affiliation 9 <sup>a</sup> Department of Pharmacy and Pharmaceutical Technology, University of 10 Navarra, 31008 - Pamplona, Spain. 11 <sup>b</sup> Centre for Nutrition Research, University of Navarra, 31080 – Pamplona, 12 Spain. 13 <sup>c</sup> Radiopharmacy Unit, University Clinic of Navarra. Av. Pío XII, 36. 31008 14 Pamplona, Spain 15 16 17 18 **Corresponding author:** Prof. Juan M. Irache 19 Dep. Pharmacy and Pharmaceutical Technology 20 University of Navarra 21 C/ Irunlarrea, 1 22 31080 - Pamplona 23 Spain 24 Phone: +34948425600 25 Fax: +34948425619 26 E-mail: jmirache@unav.es 27 28 29

30 **Short title:** Zein nanoparticles and folic acid

#### 31 Abstract

The aim of this work was to prepare and evaluate the capability of zein 32 nanoparticles for oral drug delivery. More particularly, in this work, the ability of 33 these nanoparticles to improve the oral bioavailability of folic acid is reported. 34 The nanoparticles were prepared by a desolvation process, followed by 35 purification via ultrafiltration and drying in a spray-drier apparatus. The resulting 36 nanoparticles displayed a mean size close to 200 nm with negative zeta 37 potential and a payload of 54 µg folic acid per mg nanoparticle. From the in vitro 38 release studies, it was observed that folic acid was only released from 39 nanoparticles in simulated intestinal conditions. In vivo biodistribution studies, 40 with radiolabelled or fluorescently marked nanoparticles, revealed that 41 nanoparticles remained within the gut and were capable of interacting with the 42 protective mucus layer of the jejunum. For the pharmacokinetic study, folic acid 43 44 was orally administered to rats as a single dose of 1 mg/kg.

The relatively oral bioavailability of folic acid, when encapsulated in zein nanoparticles, was around 70%: two-times higher than the value obtained with an aqueous solution of the vitamin. This fact might be explained by the mucoadhesive properties of these nanoparticles.

49

50 **Key words:** zein; nanoparticles; folic acid; bioavailability; biodistribution; 51 mucoadhesion

- 52
- 53
- 54

#### 55 Introduction

Zein, the major storage protein of maize, is located in the "zein-bodies", of 56 approximately 1 µm, that are distributed uniformly throughout the cytoplasm of 57 the corn endosperm cells between starch granules of 5-35 µm [1]. From a 58 physicochemical point of view, the key characteristic of zein is its insolubility in 59 water except at extreme pH conditions (e.g., pH 11 or above) or in presence of 60 high concentrations of urea, alcohol or anionic detergents [2]. This characteristic 61 is directly related with its composition in amino acids. Thus, zein is particularly 62 rich in glutamic acid (21-26%) and non-polar amino acids such as leucine 63 (20%), proline (10%) and alanine (10%), but it is deficient in basic and acidic 64 amino acids [3]. 65

Actually, zein is not a single protein but a mixture of four main fractions ( $\alpha$ -,  $\beta$ -, 66 v-. and  $\delta$ -zein) that differentiated in their solubility and sequence [1, 4]. Alpha-67 zein is the most abundant (around 80% of total zein) and includes two prolamin 68 groups with apparent molecular weights of 24 and 27 kDa. Beta-zein consists of 69 a methionine-rich polypeptide of 17 kDa and constitutes up to 10% of the total 70 zein; whereas y-zein is also composed of two peptides of 27 and 18 kDa. 71 72 Finally,  $\delta$ -zein is a minor fraction and has a molecular weight of about 10 kDa 73 [1, 4, 5].

Because of its hydrophobic character and deficiency in essential amino acids (e.g. lysine and tryptophan), the use of this corn protein in human food products is limited. However, zein has been proposed as material for the manufacture of a wide variety of products, including textile fibers for clothes [6], biodegradable films and plastics used for packaging [7], coatings for food and pharmaceutical dosage forms [8, 9] and scaffolds for tissue engineering [10].

In the last years, microparticles and nanoparticles from zein have also been
studied as carriers of non-polar compounds including vitamin D3 [11], curcumin
[12] or thymol [13]. Such devices were capable of protecting the loaded
compounds from stomach harsh conditions and providing a mechanism for their
controlled release [14, 15].

85 Folic acid (pteroyl-L-glutamic acid, vitamin B9) is a water soluble vitamin that is essential during periods of rapid cell division and growth. It is implicated in cell 86 replication and has an important role in the one-carbon metabolic pathway, 87 88 essential for cardiovascular and neurological functions [16]. During periods of inadequate folate intake or malabsorption, biochemical changes due to this lack 89 of folic acid/folate may result in deleterious consequences, including increased 90 91 risk for certain types of chronic diseases [17] and developmental disorders (e.g., neural tube defects) [18]. In this way, previous studies have shown that folate 92 deficiency is associated with higher incidence of mental symptoms in general 93 94 population and poor cognitive performance that may increase the risk of dementia in old age [18, 19]. Particularly in major depression, low folic acid 95 levels are frequently described in clinical studies [20]. Corroborating these 96 97 findings, a variety of controlled and open-label studies have shown that the 98 efficacy of antidepressants is influenced by folate status and may be enhanced by folic acid supplementation [21]. On the other hand, low folate intake or low 99 plasma folate concentration has also been associated with increased 100 cardiovascular and cerebrovascular risks [22]. All of these effects would be 101 related with high plasma levels of homocysteine, a cytotoxic sulfur-containing 102

amino acid that can induce DNA strand breakage, oxidative stress and apoptosis [22].

folic 105 Interestingly, acid supplementation might reduce the hyperhomocysteinaemia [23, 24]. However, the supply of folate coenzymes in 106 vivo depends primarily on the quantity and bioavailability of ingested folic 107 acid/folate and the rate of loss by urinary and fecal routes and through 108 catabolism. Additionally, folate is highly susceptible to oxidative destruction. In 109 110 fact, 50–95% of folate content in food is estimated to be lost during storage, 111 preparation, or manufacturing processes [25].

The aim of this work was to design and evaluate zein nanoparticles as carriers capable of improving the bioavailability of folic acid when orally administered. For this purpose, these zein nanoparticles were prepared by an original procedure and their capability to improve the oral bioavailability of folic acid was evaluated and compared with a conventional aqueous solution of the vitamin in rats.

- 118
- 119

#### 120 Materials and methods

#### 121 Materials

122 Zein, folic acid, lysine, arginine, pepsin, pancreatin, mannitol and sodium chloride were purchased from Sigma-Aldrich (Steinheim, Germany). Ethanol, 123 acetonitrile and o-phosphoric acid (HPLC grade) were obtained from Merck 124 (Darmstadt, Germany). Perylene-Red (BASF Lumogen® F Red 305; Lumogen 125 red) was from Kremer Pigments Inc. (Aichstetten, Germany) and Tissue-Tek® 126 OCT compound from Sakura Finetek Europe (Alphen, The Netherlands). 4',6-127 diamidino-2-phenylindole (DAPI) was obtained from Biotium Inc. (Hayward, 128 CA). Iodine 125 was from Perkin Elmer (USA). AccuDiag<sup>™</sup> Folate-Folic acid 129 ELISA Kit was purchased from Diagnostic Automation/Cortez Diagnostics Inc. 130 (USA). Deionized water (18.2 M $\Omega$  resistivity) was prepared by a water 131 purification system (Wasserlab, Spain). All reagents and chemicals used were 132 133 of analytical grade.

134

#### 135 **Preparation of zein nanoparticles**

Zein nanoparticles were prepared by a desolvation procedure followed by a
 purification step by ultrafiltration and subsequent drying in a spray-drier
 apparatus.

139

# 140 Empty zein nanoparticles (NP-Z)

Briefly, 600 mg zein and 100 mg lysine were firstly dissolved in 70 mL of a 141 142 mixture of ethanol and water (1:1 by vol.) under magnetic stirring at room temperature. Then, nanoparticles were obtained by the continuous addition of 143 70 mL purified water. The suspension was purified and concentrated by 144 145 ultrafiltration using a membrane cartridge with a 50 kDa pore size polysulfone (Medica SPA, Italy). Finally, 20 mL of an aqueous solution of mannitol (100 146 147 mg/mL) was added to the suspension of zein nanoparticles and the mixture was dried in a Büchi Mini Spray Drier B-290 apparatus (Büchi Labortechnik AG, 148 Switzerland) under the following experimental conditions: (i) inlet temperature: 149

90°C, (ii) outlet temperature: 45-50°C, (iii) air pressure: 5 bar, (iv) pumping rate:
5 mL/min, (v) aspirator of 100% and (vi) air flow: 900 L/h.

# 152153 Folic acid-loaded zein nanoparticles (FA-NP-Z)

The preparation of zein nanoparticles loaded with folic acid (FA-NP-Z) was 154 similar to that of the empty particles, with some minor adjustments. For this 155 purpose, 600 mg zein and 100 mg lysine were dissolved in 70 mL of a mixture 156 of ethanol and water (1:1 by vol.). In parallel, 200 mg folic acid was dissolved in 157 50 mL of an aqueous solution of lysine (4 mg/mL). Then, 15 mL of the aqueous 158 folic acid solution were added to the zein solution and the resulting mixture was 159 incubated at room temperature for 10 min under magnetic stirring. Finally, zein 160 161 nanoparticles were obtained by the addition of 70 mL purified water. The suspension was purified and dried as described above. 162

163

# 164 **Characterization of nanoparticles**

# 165 Size, zeta potential and morphology

The mean hydrodynamic diameter and the zeta potential of the nanoparticles were determined by photon correlation spectroscopy (PCS) and electrophoretic laser Doppler anemometry, respectively, using a Zetaplus apparatus (Brookhaven Instrument Corporation, USA). The diameter of the nanoparticles was determined after dispersion in distilled water (1:10) and was measured at 25°C with a scattering angle of 90°. The zeta potential was measured after dispersion of the dried nanoparticles in 1 mM pH 6 KCI solution.

173 The morphology and shape of nanoparticles was examined using a field emission scanning electron microscope FE-SEM (ULTRA Plus, Zeiss, The 174 Netherlands). Prior to analysis, particles were washed to remove mannitol. For 175 this purpose, spray-dried nanoparticles were resuspended in distilled water and 176 177 centrifuged at 17,000 x g for 10 min. Then, the supernatants were discarded and the obtained pellets were mounted on copper grids. Finally, the pellet was 178 shaded with an amalgam of gold/palladium during fifteen seconds using a 179 180 sputter coater (K550X Emitech, Ashford, UK).

181

# 182 Yield of the preparative process

In order to quantify the amount of protein transformed into nanoparticles, 10 mg of the nanoparticle formulation were dispersed in water and centrifuged at 17,000 x g for 20 min. Supernatants were discarded and the pellets were digested with ethanol 75%. Then, the amount of protein was quantified by UV spectrophotometry at 278 nm in an Agilent 8453 system (Agilent Technologies, USA). For analysis, calibration curves were constructed between 90 and 1200  $\mu$ g/mL (R<sup>2</sup>> 0.999; quantification limit = 143  $\mu$ g/mL).

The amount of protein forming nanoparticles in the formulation was estimated as the ratio between the amount of the protein quantified in the pellet and the total amount of zein used for the preparation of nanoparticles.

193

# 194Folic acid analysis

The amount of folic acid loaded into the nanoparticles was quantified by HPLC-UV using a previously described analytical method [26] with minor modifications. Analyses were carried out in an Agilent model 1100 Series LC 198 System coupled to a diode-array detector set at 290 nm. The data were 199 analyzed using ChemStation G2171 v. B.01.03 software (Agilent, USA). The chromatographic system was equipped with a reverse C18 Alltima column (150 200 201 mm x 2.1 mm, particle size 5 µm; Altech, USA) and a Gemini C18 precolumn 202 (particle size 5 µm; Phenomenex, CA, USA). The mobile phase, pumped at 0.25 mL/min, was a mixture of phosphoric acid (33 mM, pH 2.3) and acetonitrile 203 under gradient conditions [26]. The column was heated to 40°C and the 204 205 injection volume was 10  $\mu$ L. Under these conditions, folic acid eluted at 21.2 ± 206 0.5 min. Calibration curves were designed over the range of 2 and 200 µg/mL  $(R^2 > 0.999)$ . The limit of guantification was calculated to be 4.3  $\mu$ g/mL. 207

- For analysis, 10 mg nanoparticles was dispersed in 1 mL water and centrifuged. 208 209 The amount of encapsulated folic acid was calculated by dissolution of the pellets in 75% ethanol (1 mL). In parallel, the total amount of folic acid in the dry 210 formulations was quantified by direct digestion of 10 mg formulation with 1 mL 211 ethanol 75%. In all cases the samples were filtered through 0.45 µm 212 213 membranes before analysis. Each sample was assayed in triplicate and the results are expressed as the amount of resveratrol (µg) per mg of nanoparticles. 214 The encapsulation efficiency (EE), expressed in percentage, was calculated as 215 216 the ratio between the amount of folic acid quantified in the pellets and the total amount of folic acid quantified in the dry powder. 217
- 218

#### 219 In vitro release study

Release experiments were conducted under sink conditions at 37°C using simulated gastric fluid (SGF; pH 1.2; pepsin 0.32% w/v) and intestinal fluid (SIF; pH 6.8; pancreatin 1% w/v). The studies were performed under agitation in a Vortemp 56<sup>™</sup> Shaking Incubator (Labnet International Inc., NJ, USA) after the dispersion of the nanoparticles in the appropriate medium.

- For each specific time interval, 20 µg folic acid formulated in nanoparticles were
  resuspended in 1 mL of the corresponding simulated fluid. The different
  formulations were kept in the SGF for 2 hours before being transferred to SIF.
  At different intervals, samples were collected and centrifuged at 17,000 rpm for
  20 minutes. The amount of folic acid released was quantified by HPLC from the
  supernatants as described above.
- 231

# 232 Zein nanoparticles labelling

# 233 Radiolabelling of zein nanoparticles (<sup>125</sup>I-NP-Z)

- Zein nanoparticles were radiolabelled with lodine-125 ( $^{125}$ INa) by standard mild oxidative iodination. For this purpose, 10 mg empty zein nanoparticles were tagged with 2 iodobeads and 3.5 µL of  $^{125}$ INa in 600 µL of a mixture between PBS and water for injection (1:2 by vol). After 15 min of incubation, iodine zein nanoparticles ( $^{125}$ I-NP-Z) were obtained.
- The stability of the radiolabelling was evaluated by TLC. For this purpose, <sup>125</sup>I-NP-Z in dialysis cassettes were introduced in aqueous media and the presence of free iodide was revealed by TLC.
- 243 Lumogen red loaded in zein nanoparticles (LR-NP-Z)
- Zein nanoparticles were fluorescently labelled with Lumogen® F Red 305 (LR-NP-Z). Briefly, 2 mg Lumogen® red in acetone (5 mL) were added to the

hydroalcoholic solution of zein and lysine. Then, zein nanoparticles were formed
by the addition of 70 mL purified water. The resulting nanoparticles were
purified and dried under the same conditions described above.

The amount of Lumogen® F Red 305 was determined by colorimetry at wavelength 540 nm in a spectrophotometer Agilent 8453 system (USA). For this purpose, 10 mg of the formulations were re-suspended in purified water and centrifuged at 17,000 rpm for 20 min. Pellets were then dissolved in ethanol 75%. For quantification, standard curves of Lumogen red in ethanol 75% were used (concentration range of 5-30  $\mu$ g/mL R<sup>2</sup> ≥ 0.999).

Prior the use of fluorescently labelled nanoparticles for in vivo studies, the stability of the marker in the nanoparticles was assessed by incubation in simulated gastric (pH 1.2) and intestinal (pH 6.8) fluids.

258

# 259 *In vivo* distribution study

All of these studies were performed in male Wistar rats obtained from Harlan (Barcelona, Spain) and the protocols were approved by the Ethical Committee for Animal Experimentation of the University of Navarra (protocol number 117-12 and 059-13). Prior to the experiment, animals were placed in metabolic cages and drink provided *ad libitum*.

- For radiolabelled nanoparticles, animals (200-250 g) received a 1 mL single 265 dose of an aqueous suspension of nanoparticles (10 mg of <sup>125</sup>I-NP-Z). As 266 control, an aqueous suspension of <sup>125</sup>I was administered by oral route. Animals 267 were anesthetized with isofluorane and place in prone position on the 268 269 gammacamera. The gammagraphic studies were performed in a E.cam Dual-Head-Variable-Angle System gammacamera (Siemens Medical Systems, USA) 270 The images were obtained 2, 24 and 48 hours after the administration of the 271 radiolabelled nanoparticles. 272
- 273 For fluorescently labelled nanoparticles, a protocol previously described was used [27]. Thus, the animals received orally a single dose of 30 mg 274 nanoparticles (LP-NP-Z) dispersed in 1 mL water. Two hours later, the animals 275 276 were sacrificed and guts were removed. Jejunum portions of 1 cm were collected, cleaned with PBS, stored in the tissue proceeding medium O.C.T. 277 278 and frozen at -80°C. Each portion was then cut into 5-µm sections on a cryostat 279 and attached to glass slides. Finally, these samples were fixed with formaldehyde and incubated with DAPI (4',6-diamidino-2-phenylindole) for 15 280 minutes before the cover assembly. The presence of both fluorescently loaded 281 282 poly(anhydride) nanoparticles in the intestinal mucosa and the cell nuclei dyed with DAPI were visualized in a fluorescence microscope (Axioimager M1, Zeiss) 283 with a coupled camera (Axiocam ICc3, Zeiss) and fluorescent source (HBO 284 285 100, Zeiss. The images were captured with the software ZEN (Zeiss).
- 286

# 287 *In vivo* pharmacokinetic studies in male Wistar rats

# 288 **Pharmacokinetic studies**

Pharmacokinetic studies were performed in male Wistar rats (200-250 g) obtained from Harlan (Barcelona, Spain). Studies were approved by the Ethical Committee for Animal Experimentation of the University of Navarra (protocol number 014-10) in accordance with the European legislation on animal experiments. Prior to the experiment, animals were adaptively fed for 1 week with free access to a Folic Acid deficient diet (TD 95247, Harlan, USA) and drinking water (22±2°C; 12-h light and 12-h dark cycles; 50-60% relative humidity). Previous to the oral administration of the formulations, animals were fasted overnight to avoid interference with the absorption, allowing free access to water.

For the pharmacokinetic study, rats were randomly divided into 4 groups of 6 299 animals each. The experimental groups were an aqueous solution of folic acid 300 301 extemporaneously prepared (FA dissolved in PBS) and folic acid-loaded zein nanoparticles (FA-NP-Z) dispersed in water. As controls, a group of animals 302 was intravenously administered with a solution of folic acid in PBS and the last 303 group of rats received PBS (without folic acid) orally. The single folic acid 304 305 administered dose was 1 mg/kg body weight either orally with a blunt needle via the oesophagus into the stomach or intravenously via tail vein. 306

Blood samples were collected at set times after administration in specific serum tubes (SARSTEDT Microtube 1,1 mL Z-Gel). Volemia was recovered intraperitoneally with an equal volume of sterile saline solution pre-heated to body temperature. Samples were immediately centrifuged at 10,000 rpm for 10 min. Serum was separated into clean tubes and kept frozen at -80 °C until analysis.

313

#### 314 **Determination of folic acid in serum**

The amount of folic acid in serum was determined by an Enzyme 315 Immunoassay. Calibrator and guality control samples were prepared by adding 316 appropriate volumes of standard folic acid solution in PBS to serum. Calibration 317 curves were designed over the range 4-450 ng/mL ( $R^2 > 0.996$ ). For analysis. 318 100 mL of the serum samples were added to each well of the microtiter plate, 319 followed by the addition of 50 mL folic acid antibody. After incubation for 60 min 320 321 at room temperature, the plate was washed three times with the washing solution (PBS-Tween 20 0.5%). Then, 100 mL conjugate (anti-mouse-lgG-HRP) 322 was added into each well and after 60 min at room temperature, the plate was 323 324 washed again for three times with the washing solution. For the reaction, 100 mL of substrate was added into each well and incubated in the dark for 20 min 325 at room temperature. The reaction was stopped by the addition of 100 mL 326 327 sulphuric acid 0.5 M into each well. Finally, the absorbance was measured at 450 nm in an ELISA reader (Labsystems iEMS Reader MF). 328

Under these experimental conditions, the limit of quantification of this method was calculated to be 4 ng/mL. The recovery of folic acid from serum samples was 90.1  $\pm$  0.3%. Accuracy values during the same day (intraday assay) at low, medium and high concentrations of FA were always within the acceptable limits (less than 15%).

334

# 335 **Pharmacokinetic data analysis**

The pharmacokinetic analysis of serum concentration plotted against time data was performed using a non-compartmental model with the WinNonlin 5.2 software (Pharsight Corporation, Mountain View, USA). The following parameters were estimated: maximal serum concentration ( $C_{max}$ ), time taken to reach  $C_{max}$  ( $T_{max}$ ), area under the concentration-time curve from time 0 to  $\infty$ (AUC), mean residence time (MRT), clearance (CI), volume of distribution (V) and half-life in the terminal phase  $(t_{1/2})$ . Furthermore, the relative oral bioavailability (Fr, expressed in percentage) of folic acid was estimated as the ratio between the areas under the curve for the oral (AUC<sub>oral</sub>) and intravenous (AUC<sub>iv</sub>) administrations.

346

#### 347 Statistical analysis

The data are expressed as the mean ± standard deviation (SD) of at least three experiments. The non-parametric Kruskall-Wallis followed by Mann-Whitney Utest with Bonferroni correction was used to investigate statistical differences. In all cases, p< 0.05 was considered to be statistically significant. All data processing was performed using SPSS® statistical software (SPSS® 15, Microsoft, USA).

354

355

#### 356 **Results**

# 357 Folic acid loaded zein nanoparticles

Table 1 summarizes the main physicochemical properties of folic acid-loaded 358 359 nanoparticles. When folic acid was encapsulated into zein nanoparticles, a moderate increase in the mean size of the resulting carriers was observed 360 361 (about 164 nm for empty nanoparticles vs 193 nm for FA-NP-Z); whereas the negative zeta potential decreased from -46 mV (control nanoparticles) to -30 362 mV (folic acid-loaded nanoparticles). The folic acid loading into the zein 363 nanoparticles (FA-NP-Z) was calculated to be around 54 µg/mg nanoparticle, 364 365 with encapsulation efficiency close to 57%.

The morphological analysis by scanning electron microscopy (Figure 1) showed that folic acid-loaded zein nanoparticles consisted of homogeneous populations of spherical nanoparticles with a smooth surface and an apparent similar size to that obtained by photon correlation spectroscopy.

- 370 371 Table 1
- 372
- 373 Figure 1
- 374

# 375 *In vitro* release study

Figure 2 represents the release profile of folic acid from the zein nanoparticles 376 formulations as cumulative percentage of the vitamin released as a function of 377 time. When nanoparticles were incubated in SGF, no release of folic acid was 378 observed. On the contrary, when zein nanoparticles were assayed in SIF, the 379 release of folic followed a profile characterized by two different steps. In the first 380 381 one, approximately 70% of the loaded folic acid was rapidly released. Then, after this burst effect, the remaining vitamin was released in a sustained way up 382 to the end of the experiment (24 hours). 383

384

385 Figure 2

386

# In vivo distribution study of <sup>125</sup>I-NP-Z and Lumogen-NP-Z in the gut mucosa

Figure 3 shows the biodistribution (SPECT-CT images) of free 125-iodine (Figure 3A) and zein nanoparticles radiolabelled with 125-iodine (Figure 3B) orally administered to rats.

For those animals treated orally with the control (free 125-iodine), the 392 393 radioactivity was always found in their stomach and thyroid. On the other hand, 394 the radioactivity associated to zein nanoparticles was visualized in the stomach 2 hours after administration; although, twenty two hours later the radioactive 395 signal was also found at the thyroid and the distal areas of the colon. Finally, 48 396 397 hours after administration, the remaining activity was observed in the thyroid and stomach of animals, in which the signal was significantly lower than that 398 observed at the previous times. The activity in the thyroid demonstrates in vivo 399 400 physiologic de-iodination of iodine labelled nanoparticles.

401 402 Figure 3

403

Figure 4 shows fluorescence microscopy images of jejunum samples of animals 404 405 treated with Lumogen® red formulations. Control formulation (an aqueous 406 suspension of the fluorescent marker) was observed in the lumen of the small intestine of animals as large aggregates (Figure 4A) and no fluorescence was 407 visualized in the vicinity of the intestinal epithelium (Figure 4B). On the contrary, 408 409 when the fluorescent marker was encapsulated in zein nanoparticles, fluorescence appeared to be in the protective mucus layer, covering the surface 410 of the intestinal epithelium (Figures 4C and 4D). 411

- 412
- 413 Figure 4

414

# 415 **Pharmacokinetic studies in Wistar rats**

416 When folic acid was administered orally as aqueous solution, the levels of the vitamin in the sera of animals increased rapidly during the first 1 h post-417 administration, in which the  $C_{max}$  was reached (Figure 5). Then, the vitamin 418 419 levels decreased slowly until the end of the experiment (24 h postadministration). For the formulation based on zein nanoparticles, the levels of 420 folic acid in the sera of animals displayed a similar profile to that observed for 421 the free folic acid (FA solution). However, the serum levels of the vitamin from 422 nanoparticles were significantly higher than those observed for the aqueous 423 solution of folic acid. 424

- 425
- 426 Figure 5

427

Table 2 summarizes the pharmacokinetic parameters derived from the analysis of the data obtained after the administration of the different folic acid formulations to rats. When folic acid was administrated orally as aqueous solution, the AUC was 1.4  $\mu$ g h/mL; whereas, this parameter was 3.0  $\mu$ g h/mL when the vitamin was given after its encapsulation in zein nanoparticles. Similarly, the peak plasma concentration (C<sub>max</sub>) of folic acid in the nanoparticles was around 2- times higher than for the vitamin aqueous solution. On the
contrary, other important pharmacokinetic parameters of folic acid (e.g., volume
of distribution, clearance or half-life of the terminal phase) were similar when the
vitamin was administered as aqueous solution or loaded in zein nanoparticles.
Finally, the relative oral bioavailability of folic acid when incorporated in zein
nanoparticles was of about 70%, whereas for the folic acid aqueous solution the
oral bioavailability was only of 35%.

- 441
- 442 Table 2
- 443

# 444 **Discussion**

445 Folic acid, as other weak acid compounds, possesses a pH-dependent aqueous solubility, being insoluble in aqueous media below pH 5 [28]. In vivo, the pH of 446 the stomach contents may induce the precipitation of the vitamin in macroscopic 447 448 aggregates that, once in the small intestine (pH around 5-6), would be (at least in part) re-dissolved. However, in these pH conditions, and because of the 449 hydrophilic nature of the charged molecule, specific transporters are required 450 451 for folic acid absorption. These highly specific transporters (the reduced folate carrier, RFC, and the proton-coupled folate transporter, PCFT) are expressed at 452 453 the apical brush-border membrane of the proximal jejunum [29] in which the 454 absorption of the vitamin takes place [30].

455 On the other hand, zein is a biodegradable and biocompatible material, 456 economic to use and with a "GRAS" status [31]. In addition, zein is an 457 amphiphilic protein with an important ability to interact with solutes like drugs 458 [32] or amino acids [33]. Moreover, zein displays mucoadhesive properties [12] 459 and a relatively high resistance to the effect of digestive enzymes [3].

In this work, zein nanoparticles were prepared under mild conditions by a 460 desolvation technique after the addition of water to a hydroalcoholic solution of 461 the protein and lysine. Then nanoparticles were purified and, finally, dried in a 462 spray-drier apparatus. The presence of lysine was necessary to facilitate the 463 464 redispersion of the dry powder in water by simple manual agitation. Under these experimental conditions, folic acid-loaded zein nanoparticles displayed a mean 465 size after reconstitution of about 200 nm with a negative zeta potential of -24 466 467 mV and a low polydispersity index (Table 1). The folic acid content was close to 54 µg/mg nanoparticles, which is approximately 3-times higher than the payload 468 reported by Perez-Masiá and collaborators who used nano- and microcapsules 469 470 from either whey protein or starch [34].

Interestingly, the release of folic acid from zein nanoparticles was found to be 471 dependent of the pH conditions. Thus, under simulated gastric conditions, folic 472 473 acid was not released from zein nanoparticles. Nevertheless. when nanoparticles were incubated in SIF, a burst effect of approximately 70% of the 474 folic acid content was observed (Figure 2). These findings would be directly 475 476 related with the fact that the solubility of folic acid in water is dependent on its ionization (pKa values of 4.65, 6.75 and 9 [35, 36]). In SIF, the two carboxylic 477 acid groups of folic acid would be deprotonated, resulting in a negative net 478 charge similar to that observed for zein nanoparticles. Thus the repulsion 479 between ionized folic acid and zein would result in a rapid release of the vitamin 480 from the nanoparticles. On the other hand, after this burst effect of folic acid in 481

SIF, the remaining vitamin (around 30%) was slowly released till the end of the 482 experiment (Figure 2). This fact might be related with the capability of folic acid 483 to bind to proteins, such as albumins [37] and caseins [38], through hydrogen 484 and hydrophobic bonds. To the best of our knowledge, there is no information 485 suggesting the presence of binding sites for folic acid in zein; however, in 486 accordance with the release data, we can hypothesize that a fraction of the 487 loaded folic acid would be stabilized within the protein matrix by non-covalent 488 binding interactions. Therefore, the remaining fraction would be released slowly 489 490 during the degradation of the nanoparticles.

In the present study, the relative oral bioavailability of folic acid formulated as 491 aqueous solution was calculated to be 35%. The highest serum concentration of 492 493 folic acid occurred 1 hour after the administration, and values returned to baseline after 24 hours. These results are in line with previous data reported in 494 the literature by other research groups [39, 40]. On the other hand, zein 495 496 nanoparticles provided higher folic acid levels than the aqueous solution. As a consequence, the relative oral bioavailability of folic acid when administered 497 after its encapsulation in zein nanoparticles was calculated to be close to 70% 498 499 and 2-times higher than when administered as oral solution (Table 2). Other important aspects to highlight are that both the serum curve profiles (Figure 5) 500 501 and the primary pharmacokinetic parameters (volume of distribution, clearance, 502 serum half-life) of folic acid were independent on the formulation tested (aqueous solution and zein nanoparticles). Thus, the differences in the oral 503 504 bioavailability of the vitamin might only be due to the capabilities of zein 505 nanoparticles to both give protection against the macroscopic aggregation by precipitation of the vitamin in acidic conditions and act as carriers to transport 506 the folic acid to the absorptive membrane. 507

administered. zein nanoparticles 508 When orally remained within the 509 gastrointestinal tract for a period of at least 24 h post-administration (Figure 3). The absence of signals in the liver, spleen and lungs of animals suggested that 510 zein nanoparticles were not capable of entering into the circulation from the gut 511 512 (Figure 3). Within the gastrointestinal tract of animals, and in accordance with data from fluorescently labelled nanoparticles, these carriers would be capable 513 of interacting with the mucus layer protecting the epithelium surface (Figures 4C 514 515 and 4D). This last observation would be in line with previous data suggesting the mucoadhesive properties of zein [12, 41, 42]. 516

To sum up, zein nanoparticles would be capable of transporting the cargo to the small intestine. Once there, the mucoadhesive properties of zein would be responsible for an increase in the residence time of these carriers in the upper region of the gastrointestinal tract, in which the absorption of folic acid is favored [29, 30].

522 523

#### 524 Conclusions

Zein nanoparticles offer adequate properties for oral delivery purposes. Orally administered, these nanoparticles are localized within the gut in close contact with the gut mucosa. Regarding folic acid, its encapsulation in zein nanoparticles improved its relative oral bioavailability about 2-fold when compared with an aqueous solution of the vitamin. This fact would be related with the capability of these nanoparticles to reach the small intestine mucosaand develop mucoadhesive interactions.

532

#### 533

### 534 Acknowledgements

This work was supported by the Regional Government of Navarra (Alimentos Funcionales, Euroinnova call) and the Spanish Ministry of Science and Innovation and Gobierno de Navarra (ADICAP; ref. IPT-2011-1717-900000). Rebeca Penalva acknowledges the "Asociación de Amigos Universidad de Navarra" for the financial support.

540 541

# 542 **References**

- [1] T.J. Anderson, B.P. Lamsal, Zein extraction from corn, corn products, and
  coproducts and modifications for various applications: a review, Cereal Chem.
  88 (2011) 159–173.
- 546 [2] D. Fu, C.L. Weller, R.L. Wehling, Zein: properties, preparations, and 547 applications, Food Sci. Biotechnol. 8 (1999) 1-10.
- 548 [3] R. Shukla, M. Cheryan, Zein: the industrial protein from corn, Ind. Crop. 549 Prod. 13 (2001) 171-192.
- 550 [4] A. Esen, A proposed nomenclature for the alcohol-soluble proteins (zeins) of 551 maize (*Zea mays* L.), J. Cereal Sci. 5 (1987) 117-128.
- 552 [5] F.A. Momany, D.J. Sessa, J.W. Lawton, G.W. Selling, S. Hamaker, J.L. 553 Willett, Structural characterization of  $\alpha$ -zein, J. Agric. Food Chem. 54 (2006) 554 543-547.
- [6] G.W. Selling, A. Biswas, A. Patel, D.J. Walls, C. Dunlap, Y. Wei, Impact of
  solvent on electrospinning of zein and analysis of resulting fibers, Macromol.
  Chem. Physic. 208 (2007) 1002-1010.
- 558 [7] T. Padgett, I. Han, P. Dawson, Incorporation of food-grade antimicrobial 559 compounds into biodegradable packaging films, J. Food Protect. 61 (1998) 560 1330-1335.
- [8] H. Guo, Y. Shi, A novel zein-based dry coating tablet design for zero-orderrelease, Int. J. Pharm. 370 (2009) 81-86.
- 563 [9] H.X. Guo, J. Heinämäki, J. Yliruusi, Stable aqueous film coating dispersion 564 of zein, J. Colloid Interface Sci. 322 (2008) 478-484.
- 565 [10] J. Tu, H. Wang, H. Li, K. Dai, J. Wang, X. Zhang, The in vivo bone 566 formation by mesenchymal stem cells in zein scaffolds, Biomaterials 30 (2009) 567 4369-4376.
- [11] Y. Luo, Z. Teng, Q. Wang, Development of zein nanoparticles coated with
   carboxymethyl chitosan for encapsulation and controlled release of vitamin D3,
   J. Agric. Food Chem. 60 (2012) 836-843.
- 571 [12] A. Patel, Y. Hu, J.K. Tiwari, K.P. Velikov, Synthesis and characterisation of 572 zein–curcumin colloidal particles, Soft Matter 6 (2010) 6192-6199.
- 573 [13] D. Xiao, P.M. Davidson, Q. Zhong, Spray-dried zein capsules with co-574 encapsulated nisin and thymol as antimicrobial delivery system for enhanced 575 antilisterial properties, J. Agric. Food Chem. 59 (2011) 7393-7404.
- 576 [14] R. Paliwal, S. Palakurthi, Zein in controlled drug delivery and tissue 577 engineering, J. Control. Release 189 (2014) 108-122.

- [15] T. Zou, Z. Li, S.S. Percival, S. Bonard, L. Gu, Fabrication, characterization,
  and cytotoxicity evaluation of cranberry procyanidins-zein nanoparticles, Food
  Hydrocolloid 27 (2012) 293-300.
- [16] G. Kronenberg, M. Colla, M. Endres, Folic acid, neurodegenerative and neuropsychiatric disease, Curr. Mol. Med. 9 (2009) 315-323.
- 583 [17] R. Iyer, S. Tomar, Folate: a functional food constituent, J. Food Sci. 74 584 (2009) R114-R122.
- [18] É.H. Reynolds, The neurology of folic acid deficiency, Handb. Clin. Neurol.
   120 (2014) 927-943.
- 587 [19] M. Lövdén, L. Bergman, R. Adolfsson, U. Lindenberger, L. Nilsson, 588 Studying individual aging in an interindividual context: typical paths of age-589 related, dementia-related, and mortality-related cognitive development in old 590 age, Psychol. Aging 2 (2005) 303-316.
- [20] J. Šarris, N. Schoendorfer, D.J. Kavanagh, Major depressive disorder and
   nutritional medicine: a review of monotherapies and adjuvant treatments, Nutr.
   Rev. 67 (2009) 125-131.
- [21] R.T. Owen, Folate augmentation of antidepressant response, Drugs Today (Barc) 49 (2013) 791-798.
- 596 [22] R. Zeng, C. Xu, Y. Xu, Y. Wang, M. Wang, The effect of folate fortification 597 on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-598 analysis, Public Health Nutr. (2014) 1-8.
- [23] A. de Bree, W.M. Verschuren, A.L. Bjorke-Monsen, N.M. van der Put, S.G.
- Heil, F.J. Trijbels, H.J. Blom, Effect of the methylene tetrahydrofolate reductase
  677C-->T mutation on the relations among folate intake and plasma folate and
  homocysteine concentrations in a general population sample, Am. J. Clin. Nutr.
  77 (2003) 687-693.
- [24] S.E. Chiuve, E.L. Giovannucci, S.E. Hankinson, D.J. Hunter, M.J. Stampfer, W.C. Willett, E.B. Rimm, Alcohol intake and methylene tetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine, Am. J. Clin. Nutr. 82 (2005) 155-162.
- [25] M.K. Off, A.E. Steindal, A.C. Porojnicu, A. Juzeniene, A. Vorobey, A.
  Johnsson, J. Moan, Ultraviolet photodegradation of folic acid, J. Photochem.
  Photobiol B. 80 (2005) 47-55.
- [26] R. Penalva, I Esparza, M. Agüeros, C. Gonzalez-Nvarro, C. Gonzalez Ferrero, J.M. Irache, Casein nanoparticles as carriers for the oral delivery of
   folic acid, Food Hydrocolloid. 44 (2015) 399-406.
- 614 [27] L. Inchaurraga, N. Martín-Arbella, V. Zabaleta, G. Quincoces, I. Peñuelas, 615 J.M. Irache, *In vivo* study of the mucus-permeating properties of PEG-coated 616 nanoparticles following oral administration, Eur. J. Pharm. Biopharm. (in press)
- [28] Z. Wu, X. Li, C. Hou, Y. Qian, Solubility of folic acid in water at pH values
  between 0 and 7 at temperatures (298.15, 303.15, and 313.15) K, J. Chem.
  Eng. Data 55 (2010) 3958-3961.
- 620 [29] R. Zhao, L.H. Matherly, I.D. Goldman, Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments 621 and tissues, Exp. Rev. Mol. Med. 11 (2009)e4 (doi: 622 10.1017/S1462399409000969). 623

- [30] V.S. Subramanian, J.S. Marchant, H.M. Said, Apical membrane targeting
  and trafficking of the human proton-coupled transporter in polarized epithelia,
  Am. J. Physiol. Cell Physiol. 294 (2008) C233-240.
- [31] P. Hurtado-Lopez, S. Murdan, Formulation and characterisation of zein microspheres as delivery vehicles, J. Drug Del. Sci. Technol. 15 (2005) 267-272.
- [32] F. Sousa, A. Luzardo-Álvarez, J. Blanco-Méndez, M. Martín-Pastor, NMR
  techniques in drug delivery: application to zein protein complexes, Int. J. Pharm.
  439 (2012) 41-48.
- [33] T. Cserhati, E. Forgacs, Effect of pH and salts on the binding of free amino
   acids to the corn protein zein studied by thin-layer chromatography, Amino
   Acids 28 (2005) 99-103.
- [34] R. Pérez-Masiá, R. López-Nicolás, M.J. Periago, G. Ros, J.M. Lagaron, A.
  López-Rubio, Encapsulation of folic acid in food hydrocolloids through
  nanospray drying and electrospraying for nutraceutical applications, Food
  Chem. 168 (2015) 124-133.
- [35] M.J. ONeil, The Merck Index: An Encyclopedia of Chemicals, Drugs, and
   Biologicals, 14th ed., People's Health Publishing House, Beijing, 2006.
- [36] A.R. Patel, E.C. Bouwens, K.P. Velikov, Sodium caseinate stabilized zein
   colloidal particles, J. Agric. Food Chem. 58 (2010) 12497-12503.
- [37] P. Bourassa, H.A. Tajmir-Riahi, Locating the binding sites of folic acid with milk  $\alpha$ - and  $\beta$ -caseins, J. Phys. Chem. B. 116 (2012) 513-519.
- [38] P. Bourassa, I. Hasni, H.A. Tajmir-Riahi, Folic acid complexes with human
  and bovine serum albumins, Food Chem. 129 (2011) 1148-1155.
- [39] N.C. Alemdaroglu, U. Dietz, S. Wolffram, H. Spahn-Langguth, P. Langguth,
  Influence of green and black tea on folic acid pharmacokinetics in healthy
  volunteers: potential risk of diminished folic acid bioavailability, Biopharm. Drug
  Dispos. 29 (2008) 335-348.
- [40] P. Nguyen, R. Boskovic, P. Yazdani, B. Kapur, H. Vandenberghe, G.
  Koren, Comparing folic acid pharmacokinetics among women of childbearing
  age: single dose ingestion of 1.1 versus 5 mg folic acid, Can. J. Clin.
  Pharmacol. 15 (2008) 314-322.
- [41] S. Wongsasulak, S. Pathumban, T. Yoovidhya, Effect of entrapped αtocopherol on mucoadhesivity and evaluation of the release, degradation, and
  swelling characteristics of zein–chitosan composite electrospun fibers, J. Food
  Eng. 120 (2014) 110-117.
- [42] B. Zhang, Y. Luo, Q. Wang, Effect of acid and base treatments on structural, rheological, and antioxidant properties of  $\alpha$ -zein, Food Chem. 124 (2011) 210-220.
- 663
- 664

# 665 **Figure Captions**

666

Figure 1. Scanning electron microscopy (SEM) microphotographs obtained fromfolic acid-loaded zein nanoparticles.

Figure 2. Folic acid release profile from zein nanoparticles after incubation in
simulated gastric fluid (0-2 h) and intestinal fluid (2-48 h) under sink conditions.
Data are expressed as the mean ±SD, n=3.

673

Figure 3. Biodistribution of 125-lodine control and radiolabelled zein nanoparticles. Panels A and B show gammacamera images after oral administration of 125-lodine (3A) and 10 mg <sup>125</sup>l-NP-Z (3B) at 2, 24 and 48 hours post administration.

678

Figure 4. Fluorescence microscopy images of jejunum samples 2 hours after the oral administration of either a Lumogen® red aqueous suspension (A and B) or zein nanoparticles fluorescently labelled with Lumogen® red. Nuclei of cells were stained blue with DAPI.

Figure 5. Folic acid serum concentration vs time after a single oral administration of 1 mg/kg for the different formulations tested. i) Folic acid solution in PBS ( $\bullet$ ; FA sol), ii) Folic acid loaded in zein nanoparticles ( $\blacktriangle$ ; FA-NP-Z). Data expressed as the mean  $\pm$  SD; (n= 6).

688

689

690

691

692

# 693 Tables

Table 1. Physicochemical characterization of zein nanoparticles. NP-Z: empty
nanoparticles; FA: folic acid; FA-NP-Z: folic acid-loaded zein nanoparticles.
Data expressed as mean ± SD, n=3.

697

		Size <sup>a</sup> (nm)	PDI (nm)	Zeta Potential <sup>b</sup> (mV)	FA loading <sup>c</sup> (µg FA/ mg NP)	EE <sup>d</sup> (%)
ſ	NP-Z	164 ± 2	0.07 ± 0.01	-46.0 ± 1.5	-	-
	FA-NP-Z	193 ± 3	0.20 ± 0.06	-29.3 ± 3.1	54 ± 7	57 ± 6

698

<sup>a</sup> Determination of the nanoparticle size (nm) by photon correlation spectroscopy

<sup>b</sup> Determination of the zeta potential (mV) by electrophoretic laser Doppler anemometry

<sup>c</sup> Amount of folic acid loaded in the nanoparticles (µg FA/mg nanoparticles)

<sup>d</sup> Encapsulation efficiency (%)

702

703

Table 2. Pharmacokinetic parameters of folic acid administered as single dose of 1 mg/kg by the intravenous or oral routes as aqueous solution or loaded in zein nanoparticles. Data are expressed as mean  $\pm$  S.D, (n=6).

706

	Route	C <sub>max</sub> (µg/mL)	T <sub>max</sub> (h)	AUC (µg h/mL)	T½ (h)	CI (L/h)	Vd (L)	MRT (h)	Fr (%)
PBS	oral	-	-	-	-	-	-	-	-
FA iv	iv	5.5 ± 2.7 **	0.0	3.7 ± 0.4 **	1.2±0.6	0.06±0.01	0.10±0.05	0.9±0.2 **	100
FA sol	oral	$0.2 \pm 0.0$	1.0 ± 0.6	1.3 ± 0.3	5.9±1.9	0.06±0.02	0.44±0.07	5.7±1.6	35
FA-NP-Z	oral	0.4 ± 0.1 <sup>*</sup>	1.0 ± 0.0	3.0 ± 1.0 *	7.1±2.6	0.05±0.01	0.49±0.11	6.5±1.3	70

 $C_{max}$ : peak plasma concentration;  $T_{max}$ : time to reach plasma concentration; AUC: area under the curve; t<sup>1</sup>/<sub>2</sub>: half-life of the terminal phase; CI: clearance; Vd: volume of distribution; MRT: mean residence time Fr: relative oral bioavailability


\* Significant differences (p<0.05) vs FA sol (Mann-Whitney-U)


710 \*\*Significant differences (p<0.01) vs FA sol (Mann-Whitney-U)


711


712


713

















Oral administration



Esta obra está bajo una <u>licencia de Creative Commons Reconocimiento-</u> NoComercial-SinObraDerivada 4.0 Internacional.